1Cheng-Chung Wei J, Baraliakos X, Hunter T, et al. Ixekizumab significantly reduces pain, inflammation, and fatigue in patients with radiographic axial spondyloarthritis (r-axSpA)/ankylosing spondylitis (AS). Poster presented at: 2019 European League Against Rheumatism (EULAR); June 12-15, 2019; Madrid, Spain.
2Deodhar AA, Mease PJ, Rahman P, et al. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial spondyloarthritis: COAST-V/W 52-week results. BMC Rheumatol. 2021;5(1):35. https://doi.org/10.1186/s41927-021-00205-3
3Deodhar A, Mease P, Rahman P, et al. Ixekizumab improves fatigue, pain, and sleep up to 52 weeks in patients with radiographic axial spondyloarthritis. Poster presented at: American College of Rheumatology/ARP Annual Scientific Meeting; November 8-13, 2019; Atlanta, GA.
4van der Heijde D, Cheng-Chung Wei J, Dougados M, et al; COAST-V Study Group. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441-2451. http://dx.doi.org/10.1016/s0140-6736(18)31946-9